| Aug 22 |
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
|
| Aug 12 |
Skye Bioscience GAAP EPS of -$0.20 beats by $0.01
|
| Aug 9 |
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
|
| Jul 24 |
Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity
|
| Jul 24 |
Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
|
| Jul 11 |
Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th
|
| Jul 11 |
Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab
|
| Jul 3 |
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors
|
| Jul 1 |
Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes
|
| Jun 25 |
Skye BioScience Participating in Piper Sandler Virtual Obesity Day
|
